Clinical Research Directory
Browse clinical research sites, groups, and studies.
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Sponsor: Samsung Medical Center
Summary
Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3000
Start Date
2026-07-20
Completion Date
2031-12-31
Last Updated
2026-08-10
Healthy Volunteers
No
Interventions
Edoxaban
Edoxaban 60mg will be administered once daily orally according to the study protocol.
Apixaban
Apixaban 5mg will be administered twice a day orally according to the study protocol.
Locations (1)
Samsung Medical Center
Seoul, South Korea